

April 1, 2021 Full Updates for the Alberta Drug Benefit List (ADBL), Alberta Human Services Drug Benefit Supplement (HSDBS) and Palliative Coverage Drug Benefit Supplement (PCDBS)

Please be advised that the annual April 1, 2021, Full Updates to the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit List (HSDBS)* and the *Palliative Coverage Drug Benefit Supplement (PCDBS)* have been posted online at www.ab.bluecross.ca/dbl/publications.php

Effective April 1, 2021, the following drug products will be removed from the ADBL as the manufacturer did not submit a price to the annual Alberta Price Confirmation process:

As per the Alberta Price Policy, manufacturers with drug products currently listed on the ADBL were invited to re-quote the price of their drug products for continual listing. Please be advised that the following drug products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective April 1, 2021, as these manufacturers have chosen not to re-confirm their price.

All drug products scheduled to be removed from the ADBL have been identified as having therapeutic alternatives. *Effective April 1, 2021, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A 30-day transition period will be applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of May 1, 2021, claims will no longer pay for these products.*

Patients impacted by the removal of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health-care provider.

DIN	Product description
00000155357	Adrenalin Chloride 1 mg/ml Injection
00000545007	Apo-Acetaminophen 500 mg Tablet
00002041413	Ativan 0.5 mg Tablet
00002023695	Atropine 1% Ophthalmic Solution
00000999934	Ensure High-Protein Oral Liquid
00002495783	Jamp-Methadone Concentrate 10 mg/ml Oral Liquid
00002143879	Lidodan 2% Topical Jelly
00000989996	Vital Peptide 1 Cal
00000989997	Vital Peptide 1.5 Cal

Additionally, effective April 1, 2021, the following drug products will be removed from the ADBL as these drug products have been discontinued by the manufacturer:

The Alberta government-sponsored drug programs previously covered the following drug products; however, notification of discontinuation has been received from the manufacturers. Effective April 1, 2021, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A transition period will apply and, as of May 1, 2021, claims will no longer pay for these products. Patients impacted by the discontinuation of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health-care provider.

continued next page

PHARMACY BENEFACT

continued from previous page

DIN	Product description
00002237618	Adalat XL 20 mg Extended-Release Tablet
00002155990	Adalat XL 60 mg Extended-Release Tablet
00002241112	Avandia 2 mg Tablet
00002241113	Avandia 4 mg Tablet
00000476374	Choledyl Expectorant Oral Elixir
00000402516	DDAVP 0.1 mg/ml Nasal Solution
00002138018	Demerol 50 mg Tablet
00002437082	Duloxetine DR 30 mg Delayed-Release Capsule
00002437090	Duloxetine DR 60 mg Delayed-Release Capsule
00002245667	Euro-Cyproheptadine 4mg Tablet
00002212218	Fortaz 1 g/Vial Injection
00002212226	Fortaz 2 g/Vial Injection
00002212234	Fortaz 6 g/Vial Injection
00002398427	Methotrexate (Preserved) 25 mg/ml Injection USP
00002223767	Norprolac 0.075 mg Tablet
00002453754	Praluent 75 mg/ml Injection Syringe
00002453762	Praluent 150 mg/ml Injection Syringe
00002245919	Sandoz Diltiazem T 180 mg Extended-Release Capsule
00002429160	Sdz Alendronate/Cholecalciferol 70 mg/5600 U Tablet
00002463539	Taro-Deferasirox 250 mg Dispersible Tablet for Oral Suspension
00002049961	Tenoretic 50/25 Tablet
00002049988	Tenoretic 100/25 Tablet
00002410338	Tetrabenazine 25 mg Tablet
00000584223	Transderm-Nitro 0.2 mg/hr Transdermal Patch
00000852384	Transderm-Nitro 0.4 mg/hr Transdermal Patch
00002014165	Uniphyl 400 mg Sustained-Release Tablet
00002243684	Zyvoxam 600 mg Tablet

For a summary of all updates, please refer to the April 1, 2021, Summary of Changes for highlights of products and pricing changes.

Please note that the online *Interactive Drug Benefit List (iDBL)* is available at www.ab.bluecross.ca/dbl/idbl_main1.php; this is a near real-time application and as such, contains the most up-to-date information.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

